Illumina Hits Back at Carl Icahn ’s Grail Deal Claims and His Board Nominations

Illumina (US:ILMN) is hitting back at activist investor Carl Icahn as the genome sequencing biotech firm disputed his inflamatory claims and rejected his proposed board nominations. Icahn, who owns a 1.4% stake in Illumina, began his latest proxy battle on March 13, criticizing management for…#illumina #ilmn #carlicahn #icahn #delaware #grail #uec #alexaravanis #susantousi #svp

Source: Reuters: Health - March 29, 2023 Category: Consumer Health News Source Type: news